Oversight Committee to Hold Hearing on EpiPen Price Increases
There is justified outrage from families and schools across the country struggling to afford the high cost of EpiPens
The House Committee on Oversight and Government Reform will hold a bipartisan hearing with officials from Mylan, which dramatically increased its prices for EpiPens.
“There is justified outrage from families and schools across the country struggling to afford the high cost of EpiPens. We look forward to receiving answers next week from Mylan about its dramatic price hike for this life-saving medication. We also plan to examine ways to encourage greater competition in the EpiPen market and to speed FDA’s approval of acceptable new generic applications,” Chaffetz and Cummings said in a joint statement. “Our goal is to work together to ensure that critical medications, like the EpiPen, are accessible and affordable for all of our constituents.”
Ranking Member Cummings called for the hearing on August 25, 2016, and other Members of Congress also requested a hearing on this issue, including Rep. Grace Meng, Rep. Stephen Lynch, Rep. Tammy Duckworth, and Rep. Peter Welch.
Two weeks ago, Chaffetz and Cummings sent a bipartisan letter to Heather Bresch, the CEO of Mylan, requesting documents and communications regarding the increasing price of EpiPens, including documents relating to the company’s revenues from sales of EpiPens since 2007, manufacturing costs, and the amount of money the company receives from federal government health care programs. The company has indicated that it will begin producing documents this week.
Witnesses:
Heather Bresch
Chief Executive Officer
Mylan, Inc.
Dr. Doug Throckmorton
Deputy Director, Center for Drug Evaluation and Research
Food and Drug Administration
Where:
2154 Rayburn House Office Building
When:
Wednesday, September 21, 2016
Time:
10 a.m.
